In vivo interrogation of the function of genes implicated in tumorigenesis is limited by the need to generate and cross germline mutant mice. Here we describe approaches to model colorectal cancer (CRC) and metastasis, which rely on in situ gene editing and orthotopic organoid transplantation in mice without cancer-predisposing mutations. Autochthonous tumor formation is induced by CRISPR-Cas9-based editing of the Apc and Trp53 tumor suppressor genes in colon epithelial cells and by orthotopic transplantation of Apc-edited colon organoids. Apc∆/∆;Kras G12D/+ ;Trp53∆/∆ (AKP) mouse colon organoids and human CRC organoids engraft in the distal colon and metastasize to the liver. Finally, we apply the orthotopic transplantation model to characterize the clonal dynamics of Lgr5 + stem cells and demonstrate sequential activation of an oncogene in established colon adenomas. These experimental systems enable rapid in vivo characterization of cancerassociated genes and reproduce the entire spectrum of tumor progression and metastasis.
Recent tumor sequencing studies have identified a large number of candidate genes that are mutated in CRCs and may contribute to carcinogenesis, tumor phenotype, and treatment responses in subsets of patients 1, 2 . Traditionally, functional assessment of putative cancerassociated genes in vivo has required the development of genetically engineered mouse models (GEMMs) of CRC through extensive intercrossing or de novo generation of mice with desired genetic mutations, which is expensive and time-consuming. Most GEMMs of CRC such as the Apc Min mouse 3, 4 are also limited by delayed tumor onset (i.e., 2-4 months) and high tumor burden (i.e., 30-100 polyps) in the small intestine, which is a rare location for human intestinal tumors and precludes study of tumor progression beyond early adenomas or longitudinal studies using colonoscopy 5, 6 . Tumorigenesis can be localized to the colons of Apc fl/fl mice with either colon-specific promoters driving Cre recombinase, which are limited by slow tumor growth (i.e., 4-6 months) [7] [8] [9] , or rectal enema of adenoviral Cre recombinase, which requires colonic injury and/or time-consuming surgery [10] [11] [12] .
In addition to GEMMs, human and mouse cell lines are used to model CRC in vivo. Typical sites of cell transplantation are the mouse flank or kidney capsule, which do not recapitulate the native stroma of the colon mucosa 6 . Several groups have sought to orthotopically deliver tumor cell lines into the mouse colon, either surgically into the cecal serosa 13 (which is not the relevant tissue layer for CRC development) or into the mucosa via rectal enema 14 , injury 15 , electrocoagulation 16 , or colonoscopy-guided mucosal injection 17 . However, these orthotopic models are limited by the use of mouse or human cell lines that are not genetically defined and poorly recapitulate the histology of CRC.
The CRISPR-Cas9 nuclease genome editing system offers the ability to somatically mutate one or more genes in wild-type mice to assess their role in tumorigenesis 18 . We and others have demonstrated the feasibility of inducing tumorigenesis in the lung by lentiviral delivery of CRISPR-Cas9 components 19, 20 . CRISPR-Cas9 gene editing has been applied to engineer human CRC three-dimensional cultures, or organoids; mutations in APC, KRAS, TP53, SMAD4, and/ or PIK3CA were required for successful engraftment at ectopic sites in mice 21, 22 .
Here we describe CRISPR-Cas9-based somatic gene editing and orthotopic organoid transplantation approaches that employ colonoscopy-guided mucosal injection for primary and metastatic tumor induction in mice without cancer-predisposing mutations. We first optimized a colonoscopy-guided mucosal injection system to produce a mucosal bubble that localizes the injection to the lamina propria of the distal 4 cm of the mouse colon ( Supplementary Fig. 1a and Supplementary Video 1), based on previous reports 17, 23 . Using this In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis l e t t e r s approach, up to three injections per mouse delivering 50-100 µl each can be performed. We observed recombination in a 5-mm-diameter circular area at each injection site by bioluminescence and fluorescence in Rosa26 LSL-tdTomato/LSL-Luciferase mice receiving an adenoviral vector encoding Cre recombinase (Ad5CMVøCre), which suggests that we specifically infected colon cells at the injection location ( Supplementary Fig. 1b) .
To determine the utility of mucosal injection for viral infection of colon stem cells, we injected a lentiviral vector that incorporates the human phosphoglycerate kinase-1 (PGK) promoter driving the expression of Cre recombinase (PGKøCre) into Rosa26 LSL-tdTomato/+ mice, and then traced recombined cells by immunofluorescence. We observed infection of epithelial cells in the crypt base (the location of colon stem cells that initiate tumorigenesis). Notably, we also detected widespread recombination in stromal cells of the colon (Supplementary Fig. 1c ), but did not observe recombination in the proximal colon, small intestine, or liver by fluorescence microscopy (data not shown), indicating that viral infection of the mucosa was restricted to the epithelial cells and the lamina propria stromal cells of the colon in the injection area.
Consistent with these findings, deletion of the Apc tumor suppressor gene by injection of the PGKøCre lentivirus into the colon mucosa of Apc fl/fl mice, monitored by colonoscopy, reliably produced tumors within 6 weeks. These tumors demonstrated histological features of adenomatous change and nuclear β-catenin localization, which are characteristic of human neoplasms of the colon and aberrant activation of the Wnt signaling pathway, respectively ( Supplementary  Fig. 1d and Table 1 ). Mucosal injection of Ad5CMVøCre similarly induced rapid and efficient tumorigenesis ( Supplementary Fig. 2a ).
We next developed inducible CRC models using the tamoxifendependent Cre recombinase, CreER. CreER driven by the Villin (epithelial-specific) and Lgr5 (intestinal stem cell-specific) promoters has been used to induce intestinal tumors [24] [25] [26] . We generated Rosa26 LSL-tdTomato/+ ;Villin CreER , Apc fl/fl ;Villin CreER , and Apc fl/fl ;Lgr5 eGFP-CreER/+ mice and activated CreER locally by mucosal delivery of 4-hydroxytamoxifen (4-OHT). We observed epithelial-specific recombination in Rosa26 LSL-tdTomato/+ ;Villin CreER mice and efficient tumor formation in Apc fl/fl ;Villin CreER mice ( Supplementary Fig. 2b,c) . These tumors were biopsied for histology ( Supplementary Fig. 2c ). The tumor initiation rate was lower in Apc fl/fl ;Lgr5 eGFP-CreER/+ mice, most likely due to mosaic expression of the Lgr5 knock-in allele in the colon of this mouse ( Supplementary Fig. 2d and Table 1 ) 27 . We also efficiently induced tumorigenesis in Apc fl/fl mice with stable delivery of Cre mRNA in lipid nanoparticles ( Supplementary Fig. 3a-e and Table 1 ). Together, these findings establish CRC mouse models based on Cre-mediated excision of loxP-flanked Apc alleles in which tumorigenesis is restricted to the distal colon.
We then sought to harness the mucosal injection approach to model CRC using CRISPR-Cas9-based editing of Apc. We cloned a previously validated single guide RNA (sgRNA) that targets exon 16 of the murine Apc gene 28 into a lentiviral vector containing Cas9 and GFP (U6øsgApc-EFSøCas9-P2A-GFP) 29 . Mucosal delivery of this virus into wild-type mice resulted in tumors that expressed GFP, indicating stable lentivirus integration. GFP expression was lost in large regions of these adenomas, implicating silencing or lack of integration of the lentiviral transgene ( Fig. 1a ). In this system, tumorigenesis occurred in 34% of mice receiving two injections. The relatively low tumor initiation rate is most likely due to viral titers of approximately 1,000 transduction units (TU)/µl, secondary to the large size of the lentiviral genome (~8.1 kb) necessitated by the inclusion of Cas9 ( Table 1) .
Massively parallel sequencing of the genomic region flanking the sgRNA target site revealed clonal CRISPR-Cas9-mediated frameshift insertions or deletions in Apc. Notably, we observed distinct Apcinactivating mutations arising in equal biallelic proportions, which suggests that these tumors originated from two cells ( Supplementary  Fig. 4a ). Thus, we demonstrate the application of CRISPR-Cas9 for tracing the clonal origins of cancer, consistent with a recent report of organismal lineage tracing using CRISPR-Cas9 (ref. 30 ). This approach is useful for determining the types of mutations that are most potent in transforming cells and thereby conferring growth advantage within a multiclonal tumor.
To increase viral titer, we generated a lentivirus containing the Apc sgRNA without Cas9 (U6øsgApc-CMVøCre, or pUSCC; genome size ~4.4 kb), which produced viral titers of ~10,000 TU/µl. Mucosal injection of pUSCC-sgApc into Rosa26 LSL-Cas9-eGFP/+ mice 31 resulted in tumor formation in 92% of mice ( Fig. 1b and Table 1 ). Having shown that mucosal injection of lentivirus results in widespread stromal cell infection ( Supplementary Fig. 1c ), we sought to restrict CRISPR-Cas9 gene editing to colon epithelial cells for cancer modeling. We administered tamoxifen to Rosa26 LSL-Cas9-eGFP/+ ;Villin CreER mice to express Cas9 specifically in intestinal epithelial cells. Mucosal delivery of a U6øsgApc-EFSøturboRFP (pUSET; genome size ~3.8 kb) lentivirus resulted in efficient tumorigenesis characterized by infection of stromal and epithelial cells and CRISPR-mediated Apc editing only in Cas9-positive epithelial cells ( Fig. 1c and Table 1 ). Consistent with a tenfold increase in viral titer compared to the U6øsgApc-EFSøCas9-P2A-GFP lentivirus, we detected multiple frame-shifting Apc mutations present in similar proportions, indicating polyclonal tumors that arose from greater than ten cells of origin ( Supplementary Fig. 4b ).
U6øsgApc-EFSøturboRFP tumors that progressed for 1 year demonstrated high-grade dysplasia on histology but no local invasion or liver metastasis ( Supplementary Fig. 5a,b and data not shown). In comparison to 6-week-old tumors, 1-year-old U6øsgApc-EFSøturboRFP tumors exhibited dominance of 1-2 Apc frame-shifting mutations. These mutations most likely provided a growth advantage to the initiating cells (Supplementary Fig. 4b) .
To demonstrate the application of our in vivo gene editing system for modeling cancer-associated genes, we performed mucosal editing of the tumor suppressor Trp53 alone (i.e., pUSCC-sgTrp53 into Apc fl/fl Rosa26 LSL-Cas9-eGFP/+ mice) or in combination with Apc (i.e., hU6øsgApc-sU6øsgTrp53-EFSøturboRFP into Rosa26 LSL-Cas9-eGFP/+ ;Villin CreER mice treated with tamoxifen) ( Supplementary  Fig. 5c,d and Table 1 ). Massively parallel sequencing of the genomic region flanking the sgTrp53 target site revealed multiple frameshifting mutations in these tumors ( Supplementary Fig. 6a,b) . Together, these studies demonstrate the utility and multiplexability of in vivo somatic CRISPR-Cas9 editing for CRC modeling and assessment of gene function in mice without germline cancerpredisposing mutations.
We sought to use our mucosal injection approach to develop an in vivo model of intestinal organoid function in which cultured intestinal organoids are grown in the native colon environment of a host mouse. We derived intestinal and colon organoids from Rosa26 LSL-tdTomato/+ ; Villin CreER mice treated with tamoxifen and orthotopically injected these tdTomato + organoids into the colon mucosa of recipient mice. The engrafted organoids were visualized in vivo by fluorescence colonoscopy ( Supplementary Fig. 7a ). To demonstrate that the engrafted organoids were functional, we (1) labeled EdU + proliferating organoid cells; and (2) administered tamoxifen to mice that received Apc fl/fl ;Villin CreER intestinal organoids, and observed tumor formation ( Supplementary Fig. 7a,b) . Unlike in reports of intestinal organoid l e t t e r s transplantation by rectal enema into mice [32] [33] [34] , our approach does not require colitis or mechanical injury.
We exploited our mucosal injection technique to model CRC by orthotopically transplanting cancer cells. Syngeneic transplantation of an AKP murine CRC cell line derived from a genetically engineered mouse tumor 15 resulted in reproducible engraftment and invasive tumor formation ( Supplementary Fig. 8a and Table 1 ). However, these tumors did not reproduce the glandular histopathology of human colon adenocarcinoma.
We hypothesized that Apc-deficient intestinal organoids would engraft and form tumors in the distal colon after orthotopic transplantation. Intestinal and colon organoids were infected with U6øsgApc-EFSøCas9-P2A-GFP lentivirus, and then selected for Apc loss by culturing in media without the exogenous Wnt ligands Wnt3a and R-spondin-1 (Supplementary Fig. 8b ). These organoids exhibited CRISPR-Cas9-mediated editing at the sgApc target locus and activation of the Wnt signaling pathway by quantitative realtime (qRT) PCR for Wnt target genes ( Supplementary Figs. 8c,d,9a , and Supplementary Table 1 ). Orthotopic xenograft and syngeneic transplantation of CRISPR-Cas9-edited Apc-null intestinal organoids into immunodeficient mice and C57BL/6 mice, respectively, resulted in adenomas that extended to the epithelial surface with nuclear β-catenin localization ( Fig. 2a, Supplementary Fig. 8e , and Table 1 ). Analysis of mutations in these tumors at the sgApc binding site revealed substantial intratumoral and intertumoral heterogeneity ( Supplementary Fig. 9b ). We did not find local invasion or liver metastasis in Apc-null orthotopic tumors in immunodeficient (N = 16) and syngeneic recipients (N = 20) that progressed for 24 weeks (data not shown). No tumors formed upon transplantation of Apcnull intestinal organoids into the flanks of syngeneic mice, which suggests that the colon mucosa is a more permissive environment for intestinal organoid engraftment than the subcutaneous space (N = 5, data not shown). Our mucosal injection system complements the enema model of organoid orthotopic transplantation described by O'Rourke et al. 34 .
We modeled more advanced CRCs by infecting Apc fl/fl ;Kras LSL-G12D/+ ; Trp53 fl/fl colon organoids with Ad5CMVøCre, and then culturing them in media that contained nutlin-3 and lacked Wnt pathway agonists to generate AKP tumor organoids. These organoids developed invasive tumors with a desmoplastic stromal reaction after orthotopic, syngeneic transplantation, a cardinal feature of invasive human CRC ( Supplementary Fig. 8f and Table 1 ). 12 weeks following orthotopic engraftment into NSG (non-obese diabetic/severe combined immunodeficient gamma) mice, AKP organoids invaded the muscularis propria, local vasculature, and metastasized to the liver in 33% of recipient mice (Fig. 2b,c and Table 1 ). All mice with liver metastases exhibited primary colon tumors with invasion of the muscularis propria. These results indicate that orthotopic transplantation of murine tumor organoids can be used to model the entire spectrum of human CRC, including distant-organ metastasis. l e t t e r s Finally, we asked whether in vitro CRISPR-Cas9-based editing of organoids, followed by orthotopic transplantation, can be applied to assess gene function in vivo. We infected colon organoids derived from Apc fl/fl Rosa26 LSL-Cas9-eGFP/+ mice with U6øsgTrp53-CMVøCre lentivirus, cultured them in media without Wnt pathway agonists, and then in media with nutlin-3 to select for Apc∆/∆;Trp53-null organoids. We then orthotopically engrafted Trp53-null tumor organoids into NSG mice to model TP53-mutant CRC (Supplementary Figs. 8g, 10a ,b, and Table 1) .
We subsequently aimed to develop patient-derived orthotopic mouse models of CRC. Engraftment of human CRC cell lines efficiently l e t t e r s formed tumors that extended to the surface of the epithelium and invaded the muscularis propria, but did not reflect the histology of human CRC (Supplementary Fig. 11a,b and Table 1 ). In contrast, patient-derived orthotopic organoid xenografts produced tumors that accurately recapitulated the epithelial and stromal histology of the patient tumor. In addition, patient-derived organoid transplants formed invasive colon tumors that metastasized to the liver in 25% of mice with primary tumors at 8 weeks and in 45% of mice at 12 weeks after transplantation ( Fig. 2d,e, Supplementary Fig. 12a,b,d,e , Table 1 , and Supplementary Table 2 ). Patient-derived CRC organoids transplanted into the mouse flank formed histologically similar tumors but did not metastasize (N = 5 tumors; Supplementary  Fig. 12c and data not shown). Engraftment of patient-derived orthotopic xenografts, in which CRC tissue was digested and directly transplanted into the distal colon without exposure to tissue culture conditions, also engendered tumors that exhibited histological features of human CRC (Supplementary Fig. 11c, Table 1 , and Supplementary Table 2 ). These findings demonstrate that orthotopic transplantation of patient-derived CRC organoids robustly models primary and metastatic human CRC. Microsatellite unstable CRC is associated with prominent lymphocytic infiltration and improved survival with anti-programmed death 1 (PD-1) immune checkpoint inhibition 35 . However, xenograft models of patient-derived CRC lack a human immune system and therefore have limited utility for studying tumor immunology or immune checkpoint blockade. We derived organoids from a microsatellite instability-high (MSI-H) CRC from a patient with Lynch syndrome (patient B; see Supplementary Table 2 ). We then orthotopically transplanted the MSI-H organoids into NSG mice with a reconstituted human immune system, which elicited a human lymphocytic infiltrate that is similar to what is observed in MSI-H patient tumors. (Supplementary Fig. 12f ) 36 .
Lgr5 (leucine-rich repeat containing G-protein-coupled receptor 5) marks a subpopulation of small intestinal adenoma stem cells that generate new adenoma cells 26 . However, the mouse models previously used for Lgr5 cell labeling and retracing do not model colon adenomas and do not permit gene mutation in established adenomas. We used our orthotopic transplantation system to overcome these limitations and trace the lineage of Lgr5 + cells in established colon adenomas. We generated Lgr5 CreER/+ ;Rosa26 LSL-tdTomato/+ mice, derived colon organoids, inactivated Apc by in vitro lentiviral infection (i.e., U6øsgApc-EFSøCas9-P2A-GFP), and orthotopically engrafted these tumor organoids into NSG mice to generate tumors in vivo that were visualized by colonoscopy 2 weeks post-injection. Tumor-bearing mice were then administered a tamoxifen pulse to label Lgr5 + cells with tdTomato ( Fig. 3a) . Tumors were visualized with fluorescence colonoscopy and immunofluorescence 2 days, 3 weeks, and 6 weeks after labeling (Fig. 3b,c) . Lgr5 cell-derived populations increased in proportion to the total tumor area and in average clone size at 3 and 6 weeks after labeling compared to labeling at 2 days (Fig. 3d,e) . Notably, tdTomato + areas contained more proliferating EdU + cells compared to tdTomatoareas of the tumors, indicating that clones derived from Lgr5 + cells harbored increased proliferative potential (Fig. 3f) . Finally, we activated oncogenic Kras in Lgr5 + tumor cells by administrating tamoxifen to Apc-null Lgr5 CreER/+ ;Rosa26 LSL-tdTomato/+ ;Kras LSL-G12D/+ orthotopic tumors (Fig. 3g,h) . These results reveal cancer stem cell activity for Lgr5 tumor cells in colon adenomas and demonstrate the application of our orthotopic transplantation model for sequential mutagenesis in established colon tumors.
Our in situ epithelial gene editing and orthotopic transplantation systems provide considerable advances over standard mouse models of CRC: (1) tumors are located in the appropriate tissue compartment (i.e., the colon) and correct tissue layer (i.e., lamina propria); (2) organoids require only Apc loss for orthotopic engraftment, instead of multiple additional oncogenic mutations that are required for engraftment at other sites 21, 22 ; (3) tumors form within a few weeks; (4) tumors are seen in almost all experimental mice; (5) tumors are longitudinally monitored with colonoscopy; (6) tumors with advanced mutations reproduce key pathological features of human CRC, including progression from primary cancer, invasion of the muscularis propria, and liver metastasis 5,37,38 ; (7) customized viral vectors reduce the cost and time required to functionally interrogate cancer-associated genes; (8) tumors are quickly induced with defined CRISPR-Cas9-based genetic alterations in vivo or in organoids without the time-consuming need to generate mutations in the germline; and (9) orthotopic transplantation of Apc-edited organoids permits lineage tracing and sequential mutagenesis in established adenomas.
An important goal of cancer modeling is to reproduce primary and metastatic disease in vivo for preclinical research and for clinical applications. Patient-derived CRC organoids have been shown in vitro to recapitulate molecular, genetic, and pathological features of the original tumors, but to date have been engrafted only into ectopic sites. Organoid-based models of metastatic CRC are limited to seeding of distal organs from the kidney capsule or spleen 39, 40 . We demonstrate the use of patient-derived organoids to model tumor formation in the native colon environment with tumor and stromal histology that accurately reflects the patient's disease. Finally, we apply our orthotopic transplantation system to model patient-derived primary cancer, local tumor invasion, and liver metastasis.
METHodS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 45 were maintained on a mixed C57BL/6J × 129SvJ genetic background. Orthotopic transplantation experiments with C57BL/6 organoids were performed on syngeneic C57BL/6 or NOD SCID gamma (NSG) 46 recipient mice. Mixed-background mouse organoid and human organoid engraftments were performed in NSG recipient mice. Humanized mice were developed as previously described 46 . Approximately equal numbers of male and female mice of 6-10 weeks age were used for all experiments. Where indicated, mice were injected intraperitoneally with tamoxifen (Sigma-Aldrich, catalog # T5648) suspended in sunflower seed oil (Spectrum Chemical, catalog # S1929) at a concentration of 10 mg/ml and 250 µl per 25 g of body weight.
Generation of lentiviral vectors and sgRNA cloning.
The pL-CRISPR-EFSøGFP vector was obtained from Addgene (#57818) 29 . The pSECC vector has been previously described and is available from Addgene (#60820) 19 . The U6øsgRNA-CMVøCre (pUSCC) or U6øsgRNA-EFSøturboRFP (pUSET) lentiviral vectors were constructed by assembling four parts with overlapping DNA ends using modular Gibson assembly of lentiviruses, as previously described 47 . Briefly, a 2.2 kb part (corresponding to the U6-Filler fragment from pSECC), a 0.3 kb part (corresponding to the EFS promoter from pSECC), a 0.5 kb part (corresponding to the CMV promoter from CMV-GFP, for pUSCC (Addgene #68485) 47 ), a 0.7 kb part (corresponding to tur-boRFP in pTRIPZ (Dharmacon, catalog # RHS4740), for pUSET) or a 1 kb part (corresponding to Cre recombinase from pSECC, for pUSCC), and a 5.7 kb lentiviral backbone were assembled using Gibson assembly following the manufacturer's protocol (New England BioLabs Gibson Assembly Master Mix; catalog # E2611S). For sgRNA cloning, the pUSCC, pUSET, and U6-sgApc-EFS-Cas9-2A-GFP vectors were digested with BsmBI and ligated with a BsmBI-compatible annealed sgRNA oligo targeting exon 16 in Apc (target sequence GTCTGCCATCCCTTCACGTTAGG, PAM sequence underlined), as previously reported 28 . The pUSCC vector was digested and ligated with a previously described sgRNA targeting exon 7 in Trp53 (target sequence GTGTAATAGCTCCTGCATGGGGG, PAM sequence underlined) 48 . The paired guide hU6-sgApc-sU6-sgTrp53-EFS-turboRFP vector was cloned using the above sgRNAs using a previously described system 49 .
Lentivirus production. Lentivirus was produced by co-transfection of 293T cells with lentiviral backbone constructs and packaging vectors (pSpax2 and pMD2.G) using TransIT-LT1 (Mirus Bio, catalog # MIR 2300). Supernatant was collected 48 and 72 hours after transfection, concentrated by ultracentrifugation at 25,000 r.p.m. for 2 hours and resuspended in an appropriate volume of OptiMEM (Invitrogen, catalog # 31985-070). Viral titer was calculated by serial infection of 293T cells (for lentiviruses containing either GFP or tur-boRFP) or GreenGo Cre reporter cells (for lentiviruses containing Cre) 19 .
Murine intestinal organoid culture and lentiviral infection.
As previously reported 23 and briefly summarized here, small intestines and colons were removed, washed with cold PBS−/−, opened laterally and cut into 3-to 5-mm fragments. Pieces were washed multiple times with cold PBS−/− until clean, washed 2-3 with PBS−/− 10 mM EDTA (Ambion, catalog # am9261), and incubated on ice for 90-120 min while mixing at 30-min intervals. Crypts were then mechanically separated from the connective tissue by shaking, and filtered through a 70-µm mesh into a 50-ml conical tube to remove villus material (for small intestine) and tissue fragments. Crypts were then resuspended in 50% L-WRN conditioned media as previously described 50 , henceforth referred to as conditioned media (derived from L-WRN cells, a kind gift from Thaddeus Stappenbeck, Washington University) and manually counted. Crypts were embedded in growth factor-reduced Matrigel (Corning, catalog # 356231), diluted 3:4 in conditioned media into 24-well plates (Olympus, catalog # 25-107) at a density of ~750 crypts in 75 µl total volume per well, and incubated with conditioned media supplemented with 10 µM of the p160 ROCK inhibitor Y-27632 dihydrochloride monohydrate (APExBIO, catalog # A3008) to prevent cell death by anoikis.
Murine intestinal organoids were infected with lentivirus based on a protocol previously described for organoid retroviral infection 51 . Briefly, 2-3 days following culture of intestinal crypts, media was changed for culture media plus 10 mM nicotinamide (Sigma-Aldrich, catalog # N3376). At this point, organoids were cystic or round in appearance, which indicates the presence of healthy stem cells. The following day, organoids were disrupted mechanically by pipetting up and down 30 to 50 times with a 1,000-µl pipette. At this stage, the organoids were ideally small clumps of fewer than ten cells. If mechanical dissociation was not sufficient, then organoids were gently dissociated enzymatically with 1× TrypLE Express (Life Technologies, catalog # 12604-021) at 37 °C for 1-5 min. Organoids were then resuspended in a 24-well plate with culture media supplemented with 10 µM Y27632, 10 mM nicotinamide, and 8 µg/ml Polybrene (Sigma-Aldrich, catalog # TR-1003). The plate was centrifuged for 60 min at 600g at 32 °C (spinoculation), and then incubated at 37 °C for 6 h. Infected organoids were then embedded in Matrigel and cultured with culture media plus 10 µM Y27632 and 10 mM nicotinamide. For sgApc CRISPR-Cas9 viral infections, organoids were maintained in conditioned media for 7 d to permit Cas9-mediated editing of Apc, then in media without Wnt3a or R-spondin-1 (Advanced DMEM/F12 (Life Technologies, catalog # 12634-028) supplemented with 1× N2 (Life Technologies, catalog # 17502-048) and 1× B27 (Life Technologies, catalog # 17504-044)) for selection of Apc-deficient organoids.
AKP colon organoids were generated by culturing colon organoids from Apc fl/fl ;Kras LSL-G12D/+ ;Trp53 fl/fl mice and infecting with Ad5CMVøCre. CRISPR-Trp53 colon organoids were created by culturing organoids from Apc fl/fl ;R26 LSL-Cas9-eGFP/+ mice and infecting with U6øsgTrp53-CMVøCre lentivirus. AKP and Apc∆/∆, p53-null organoids were selected in media without Wnt3a or R-spondin-1 supplemented with 10 µM nutlin-3 (Cayman Chemical, catalog # 10004372).
Murine colonoscopy and mucosal injection.
Optical and fluorescence colonoscopy was performed using the Image 1 H3-Z Spies HD Camera System (part TH100), Image 1 HUB CCU (parts TC200, TC300), 175 Watt D-Light Cold Light Source (part 20133701-1), AIDA HD capture system, Hopkins Telescope (part 64301AA), and fluorescent filters in the tdTomato (emission 554 nm) and GFP channels (emission 509 nm) (all from Karl Storz).
For mucosal injections, Ad5CMVøCre, 4-hydroxytamoxifen (Calbiochem, catalog #579002) or lentivirus were resuspended in OptiMEM, and then delivered to the colon mucosa of recipient mice (ideally 6-10 weeks old) by optical colonoscopy using a custom injection needle (Hamilton Inc., 33 gauge, small Hub RN NDL, 16 inches long, point 4, 45-degree bevel, like part number 7803-05), a syringe (Hamilton Inc., part number 7656-01), a transfer needle (Hamilton Inc., part number 7770-02), and a colonoscope with integrated working channel (Richard Wolf 1.9 mm/9.5 French pediatric urethroscope, part number 8626.431). For each injection, the tip of the injection needle was first placed into the colon mucosa. 50-100 µl of media was then quickly delivered by an assistant to form a large bubble (Supplementary Video 1) . 2-3 injections were performed per mouse.
For orthotopic organoid transplantations, organoids were gently mechanically dissociated, resuspended in 90% minimal media (Advanced DMEM supplemented with N2 and B27) and 10% Matrigel, and then transplanted into recipient mice. Mice underwent colonoscopy 4-8 weeks following lentiviral injection or organoid transplantation to assess tumor formation. Colonoscopy videos and images were saved for offline analysis. Tumor size was quantified using ImageJ, as previously described 52 . Following euthanasia, the distal colons were excised and fixed in 10% formalin, sectioned, and examined by hematoxylin and eosin staining to identify adenomas. Alternatively, tumors were fixed for 1 hour in 4% paraformaldehyde in PBS, then overnight in 25% sucrose solution, and frozen for sectioning.
Human colorectal cancer organoid collection and isolation. 0.5-1 cm 3 portions of fresh CRC surgical specimens were obtained from patients undergoing surgery for CRC at Tufts Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital/Dana Farber Cancer Institute. Cancer tissue was selected by the clinical pathologist only if not required for clinical diagnosis. Samples were placed in cold PBS and transported to the Koch Institute at MIT. The respective Institutional Review Board committees and the Massachusetts Institute of Technology Committee on the Use of Humans as Experimental Subjects approved the study protocols. Informed consent was obtained from all subjects. Cancer tissues were grown into organoids as previously described 39 , with minor modifications. Briefly, tissues were finely minced, and then digested with collagenase Type 1 (200 units in 5 ml PBS) 32 °C for 5-10 min. After digesting into clumps of cells, the sample was filtered through a 100-µm mesh and seeded into Matrigel in 24-well plates (50-75 µl per well). Following Matrigel polymerization (10 min at 37 °C), 650 µl of human culture media (conditioned media, 1× N2, 1× B27, EGF 40 ng/ml (PeproTech, catalog # 315-09), 3 µM SB202190 (Sigma-Aldrich, catalog # S7067), 500 nM A83-01 (Tocris, catalog # 2939), 10 µM Y-27632 dihydrochloride monohydrate, 1 µM N-acetyl-l-cysteine (Sigma-Aldrich, catalog # A7250), 10 mM nicotinamide, 10 nM human gastrin I (Sigma-Aldrich, catalog # G9020), and 100 µg/ml primocin (InvivoGen, catalog # ant-pm-1). Two days after organoid formation, tumor organoids were selected by changing media to ADMEM supplemented with 1× penicillin/streptomycin, 100 µg/ml primocin, 1× N2, and 1× B27. Immunohistochemistry. As previously described, tissues and organoids were fixed in 10% formalin, paraffin embedded, and sectioned 23, 53 . Consecutive sections were prepared using a Leica RM2255 rotary microtome (Leica Biosystems, Nussloch, Germany). H&E and trichrome stains were performed according to standard procedures. For β-catenin (mouse monoclonal β-catenin; 1:200, BD Biosciences, catalog # 610154), antigen retrieval was performed with Borg Decloaker RTU solution (Biocare Medical, catalog # BD1000) in a pressurized Decloaking Chamber (Biocare Medical) for 3 minutes. Biotin-conjugated donkey anti-mouse secondary antibody was used (Jackson ImmunoResearch, catalog # 715-066-150). The Vectastain Elite ABC immunoperoxidase detection kit (Vector Labs, catalog # PK-6101) followed by Dako Liquid DAB+ Substrate (Agilent Technologies, catalog # K3468) was used for visualization.
For CDX2 (rabbit monoclonal CDX2; 1:1250, Abcam, catalog # ab76541), Cytokeratin 20 (rabbit monoclonal human specific Cytokeratin 20; 1:500, Abcam, catalog # ab76126), LYVE1 (rabbit polyclonal LYVE1; 1:200, Abcam, catalog # ab14917), and CD3 (rabbit monoclonal CD3; 1:200, Abcam, catalog # ab16669), CD31 (1:50, Abcam, catalog # ab28364), and the human specific nuclear envelope marker Lamin A+C (1:2500, Abcam, catalog # ab108595), sections were dried at 60°C for 1 hour, dewaxed and rehydrated before treatment with heat-induced heat-induced epitope retrieval (HIER). The sections were then incubated in 10 mM sodium-citrate (pH 6.0) or 10mM Tris (pH 9.0) buffered solutions containing 0.05% Tween and heated at 120°C for 2 min using a pressure cooker. To obtain consistent and reliable staining an automated staining system (LabVision Autostainer 360, ThermoFisher Scientific) was used. The sections were subsequently cooled and placed onto the Autostainer. To destroy all endogenous peroxidase and alkaline phosphatase activity in the tissue, the sections were pretreated using BLOXALL blocking solution (Vector Laboratories, catalog # SP-6000) for 10 minutes. After a blocking step with normal horse serum, the sections were incubated with the individual primary antibody for 1 hour followed by several washes and secondary ImmPRESS polymer detection systems (Vector Laboratories), according to the manufacturer's protocols. The Vulcan Fast Red Chromogen Kit 2 (red staining; Biocare Medical, catalog # FR805) and the DAB Quanto Chromogen and Substrate (brown staining; ThermoFisher Scientific, catalog # TA-060-QHDX) were applied as substrates and hematoxylin used as counterstain. For multiple stainings, following HIER and blocking steps, the individual antibodies were incubated consecutively using the chromogens indicated above. Image documentation was performed using the Leica Aperio AT2 slide scanner system. Each antibody has been validated for use in mouse and human tissues, as detailed on the manufacturers' websites.
Immunofluorescence. Immunofluorescence on cryosections was performed as previously described 54 . Briefly, 7 µm cryosections of intestines were airdried, fixed with cold acetone, washed with PBS and blocked with donkey immunomix (i.e., 5% normal donkey serum, 0.2% bovine serum albumin, 0.05% sodium azide, and 0.3% Triton-X100 in PBS). The following primary antibodies were used for immunostaining of mouse tissues: rabbit β-catenin (1:100, Abcam, catalog # ab32572), mouse β-catenin (1:100, BD Biosciences, catalog # 610154), rabbit polyclonal lysozyme (1:250, ThermoFisher Scientific, catalog # RB-372-A1), rat EpCAM-APC (1:500, Biolegend, catalog # 17-5791-82). Sections were washed with PBS containing 0.3% Triton-X100. Primary antibodies were detected with the appropriate Alexa 488, 594 or 647 secondary antibodies (ThermoFisher Scientific). Tissues were post-fixed in 1% paraformaldehyde and mounted in Vectashield with DAPI (VectorLabs, catalog # H1200). Immunofluorescence images were captured using a Nikon A1R confocal microscope using 10× or 20× air objectives and multichannel scanning in frame mode (pinhole 1.2 Airy units). For identification of proliferating cells, mice harboring orthotopic tumors were injected intraperitoneally with 1 mg of 5-ethynyl-2-deoxyuridine (EdU; Setareh Biotech, catalog # 61135-33-9) 4 hours before euthanasia. EdU was detected in cryosections using the Click-iT EdU Alexa Fluor 488 Imaging Kit (ThermoFisher Scientific, catalog # C10337) according to the manufacturer's protocol. Each antibody has been validated for use in mouse intestinal tissues, as detailed on the manufacturers' websites.
Bioluminescence imaging. Colons of wild-type mice were injected with lipid nanoparticles containing firefly luciferase mRNA or firefly luciferase mRNA alone. Rosa26 LSL-tdTomato/LSL-Luciferase mice were injected with Ad5CMVøCre under colonoscopy guidance. Two days later, mice were injected intraperitoneally with 100 mg/kg d-luciferin, which was allowed to circulate for 10 min, followed by euthanasia and dissection of colons for bioluminescence imaging (IVIS, Caliper Life Sciences).
Lipid nanoparticle synthesis.
Lipid nanoparticles (LNPs) were synthesized as previously described 55 . In brief, an ethanol phase containing the lipids and an aqueous phase containing the mRNA were mixed in a microfluidic chip device. The aqueous phase consisted of 300 µL of Cre mRNA (1 mg/mL in 10 mM TRIS-HCL, TriLink Biotechnologies,), 155 µL of citrate (100 mM, pH 3), and 1,097µL of water. The ethanol phase contained the ionizable lipid ckk-E12 (3.0 mg, synthesized in our laboratory, as previously described 56 
Electron microscopy. A cryogenic transmission electron microscopy (TEM)
picture was taken of LNPs in a buffered solution on a lacey copper grid coated with a continuous carbon film. The grid was then mounted on a Gatan 626 cryo-holder equipped within a TEM column. The specimen and holder tip were continuously cooled by liquid nitrogen during transfer into the microscope and subsequent imaging. Imaging was performed using a JEOL 2100 FEG microscope using a minimum dose method that was essential to avoiding sample damage under the electron beam. The microscope was operated at 200 kV and with a magnification setting of 60,000 for assessing particle size and distribution. All images were recorded on a Gata 2kx2k UltraScan CCD camera.
Massively parallel sequencing.
A genomic region containing the sgApc target sequence was amplified using Herculase II Fusion DNA polymerase and gel purified (Forward primer 5′ to 3′: AAGACCAGGAAGCCTTGTGG; Reverse primer 5′ to 3′: GCTTGTGTCTCTGCTTACTCC). Sequencing libraries were prepared from 50 ng of PCR product using the Nextera DNA Sample Preparation Kit (Illumina) according to manufacturer's instructions and sequenced on Illumina MiSeq sequencers to generate 150-base pair (bp) paired-end reads. The sgTrp53 target sequence was amplified and sequenced using the above methods and the following primers: Forward primer 5′ to 3′: ATTCCCGGCTGCTGCAGGTC; Reverse primer 5′ to 3′: GGCGGGACTCGTGGAACAGAA).
Bioinformatic analysis of target loci. Illumina MiSeq reads (150-bp pairedend) were trimmed to 120 bp after reviewing base quality profiles, in order to drop lower quality 3′ ends. Traces of Nextera adapters were clipped using the FASTX toolkit (Hannon Lab, Cold Spring Harbor Laboratory) and pairs with each read greater than 15 bp in length were retained. Additionally, read pairs where either read had 50% or more bases below a base quality threshold of Q30 (Sanger) were dropped from subsequent analyses. The reference sequence of the target locus was supplemented with 10-bp genomic flanks and was indexed using an enhanced suffix array 57 . Read ends were anchored in the reference sequence using 10-bp terminal segments for a suffix array index lookup to search for exact matches. A sliding window of unit step size and a maximal soft-clip limit of 10 bp was used to search for possible anchors at either end of each read. For each read, optimal Smith-Waterman dynamic programming alignment 58 was performed between the reduced state space of the read sequence and the corresponding reference sequence spanning the maximally distanced anchor locations. Scoring parameters were selected to allow for sensitive detection of short and long insertions and deletions while allowing for up to four mismatches, and the highest scoring alignment was selected. Read pairs with both reads aligned in the proper orientation were processed to summarize the number of wild-type reads and the location and size of each insertion and deletion event. Overlapping reads within pairs were both required to support the event if they overlapped across the event location. Additionally, mutation events and wild-type reads were summarized within the extents of the sgRNA sequence and PAM site by considering read alignments that had a minimum of 20-bp overlap with this region. Mutation calls were translated to genomic coordinates and subsequently annotated using Annovar 59 . The alignment and post-processing code was implemented in C++ along with library functions from SeqAn 60 and SSW 61 and utility functions in Perl and R (http://www.R-project.org). Mutation calls were subjected to manual review using the Integrated Genomics Viewer (IGV) 62 .
CRC cell lines.
Murine CRC cell lines were derived from AKP genetically engineered tumors, as previously described 15 . Following mechanical abrasion of the distal colon, 100 µl Ad5CMVøCre (University of Iowa Viral Vector Core Facility; 10 10 TU/µl) was delivered by rectal enema to C57BL/6 Apc fl/fl ;Kras LSL-G12D/+ ;Trp53 fl/fl mice during laparotomy to restrict adenoviral delivery to the distal colon and initiate tumorigenesis. Tumors were extracted, finely minced, digested with collagenase Type 1 (200 units in 5 ml PBS) (Worthington, catalog # LS004196) and grown (DMEM supplemented with 1× penicillin/ streptomycin and 10% FBS) as immortalized two-dimensional cultures. Cell cultures were then sorted as EpCAM + single cells by fluorescence-activated cell sorting and expanded to derive pure AKP cell lines. LS174 and HT29 human CRC cells were obtained from American Type Culture Collection. Both murine AKP and human LS174 cells tested negative for mycoplasma contamination.
In situ hybridization for human CDX2. Automated in situ hybridization (ISH) assays for human CDX2 mRNA were performed using ViewRNA eZL Detection Kit (ThermoFisher Scientific, catalog # 19500) on the Bond RX immunohistochemistry and ISH Staining System with BDZ 6.0 software (Leica Biosystems). Formalin-fixed paraffin-embedded (FFPE) tissue sections on slides were processed automatically from deparaffinization, through ISH staining to hematoxylin counterstaining. Briefly, 5 mm-thick sections of formalinfixed tissue were baked for 1 hour at 60 °C and placed on the Bond RX for processing. The Bond RX user-selectable settings were as follows: ViewRNA eZ-l Detection 1-plex (Red) protocol; ViewRNA Dewax1 Preparation protocol; ViewRNA HIER 10 min, ER1 (95); ViewRNA Enzyme 2 (10); ViewRNA Probe Hybridization. With these settings, the RNA unmasking conditions for the FFPE tissue consisted of a 10-min incubation at 95 °C in Bond Epitope Retrieval Solution 1 (Leica Biosystems, catalog # AR9961), followed by 10 minutes incubation with Proteinase K from the Bond Enzyme Pretreatment Kit at 1:1,000 dilution (Leica Biosystems, catalog # AR9551). Human CDX2 Ez probes were diluted as 1:40 and 1:20, respectively, in ViewRNA Probe Diluent (ThermoFisher Scientific). After the run, slides were rinsed with water, air-dried for 30 minutes at room temperature and mounted using Dako Ultramount (Agilent Technologies, catalog # S1964), and visualized using a standard brightfield microscope.
Statistics. For analysis of the statistical significance of differences between two groups, we used two-tailed Student's t-tests based on a normal distribution of the data. All error bars denote standard deviation. All samples represent biological replicates. No samples or animals were excluded from analysis, and sample size estimates were not used. Animals were randomly assigned to groups. Studies were not conducted blind.
Data availability. Raw sequence reads for targeted loci were deposited in the NCBI Sequence Read Archive under BioProject ID PRJNA382238.
